Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials.
Matthew A BrownMartin RudwaleitFloris A van GaalenNigil HaroonLianne S GenslerCarmen FleurinckAlexander MartenUte MassowNatasha de PeyrecaveThomas VauxKaty WhiteAtul A DeodharIrene van der Horst-BruinsmaPublished in: Annals of the rheumatic diseases (2024)
Bimekizumab, a dual-IL-17A/F inhibitor, may confer protective effects for uveitis in patients with axSpA.